New compounds in the treatment of IBD (ECCO 2017)
Never before in the history of IBD have there been so many promising compounds in the pipeline. In a scientific session dedicated to new compounds, leading investigators discussed… read more.
Never before in the history of IBD have there been so many promising compounds in the pipeline. In a scientific session dedicated to new compounds, leading investigators discussed… read more.
Dr Filip Baert (Roeselare, Belgium) gives a summary of his session on trial endpoints vs therapeutic objectives. he also discusses the role of ECCO in improving the data generated in… read more.
Predicting disease years before diagnosis is a passion for Professor Jean-Frederic Colombel (Icahn School of Medicine at Mount Sinai, NY, USA). Here he discusses 2 studies presented at… read more.
In it for the long haul – managing the complexity of Crohn’s disease by Maria Dalby Michael Kamm (Melbourne, Australia), Remo Panaccione (Alberta, Canada) and Stefan Schreiber (Kiel,… read more.
In it for the long haul – managing the complexity of Crohn’s disease by Maria Dalby Michael Kamm (Melbourne, Australia), Remo Panaccione (Alberta, Canada) and Stefan Schreiber (Kiel,… read more.
The future is now – importance of the IBD nurse in patient care. by Maria Dalby Marian O’Connor (St Mark’s Hospital, London, UK ), Silvio Danese (Milan, Italy)… read more.
Silvio Danese, Humanitas Clinical and Research Hospital, Milan, Italy. Article by Maria Dalby – The current paradigm for managing inflammatory conditions is to suppress the inflammatory response by… read more.
New drugs in IBD – by Maria Dalby Tofacitinib Two randomised placebo-controlled phase 3 studies (OCTAVE Induction 1 and 2) show that tofacitinib, an oral small-molecule Janus kinase… read more.